Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
The International Journal of Neuropsychopharmacology
|
February 24, 2010
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study
Nizar El-Khalili, Mark Joyce, Sarah Atkinson, et al.
Journal of Affective Disorders
|
August 10, 2010
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study
Brian Bortnick, Nizar El-Khalili, Michael Banov, et al.
Frontiers in Psychiatry
|
November 3, 2025
Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression
Christine Zu Eulenburg, Daniel Gehrlach, Marius Myhsok, et al.
The International Journal of Neuropsychopharmacology
|
May 16, 2013
Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies
Madhukar H Trivedi, Borwin Bandelow, Koen Demyttenaere, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
January 21, 2015
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy
Hans-Jürgen Möller, Koen Demyttenaere, Bengt Olausson, et al.
International Clinical Psychopharmacology
|
October 11, 2013
Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment
Michael Bauer, Koen Demyttenaere, Nizar El-Khalili, et al.
International Clinical Psychopharmacology
|
December 15, 2015
Content validity of the Sheehan Irritability Scale in patients with major depressive disorder
Sally Mannix, Mariam Hassan, Raj Tummala, et al.
JAMA Network Open
|
June 24, 2026
Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials
Martin Walter, Christine Zu Eulenburg, Ani Damyanova, et al.
Schizophrenia Research
|
February 16, 2015
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
John M Kane, Aleksandar Skuban, John Ouyang, et al.
The American Journal of Psychiatry
|
April 18, 2015
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Christoph U Correll, Aleksandar Skuban, John Ouyang, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
The International Journal of Neuropsychopharmacology
|
February 24, 2010
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study
Nizar El-Khalili, Mark Joyce, Sarah Atkinson, et al.
Journal of Affective Disorders
|
August 10, 2010
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study
Brian Bortnick, Nizar El-Khalili, Michael Banov, et al.
Frontiers in Psychiatry
|
November 3, 2025
Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression
Christine Zu Eulenburg, Daniel Gehrlach, Marius Myhsok, et al.
The International Journal of Neuropsychopharmacology
|
May 16, 2013
Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies
Madhukar H Trivedi, Borwin Bandelow, Koen Demyttenaere, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
January 21, 2015
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy
Hans-Jürgen Möller, Koen Demyttenaere, Bengt Olausson, et al.
International Clinical Psychopharmacology
|
October 11, 2013
Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment
Michael Bauer, Koen Demyttenaere, Nizar El-Khalili, et al.
International Clinical Psychopharmacology
|
December 15, 2015
Content validity of the Sheehan Irritability Scale in patients with major depressive disorder
Sally Mannix, Mariam Hassan, Raj Tummala, et al.
JAMA Network Open
|
June 24, 2026
Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials
Martin Walter, Christine Zu Eulenburg, Ani Damyanova, et al.
Schizophrenia Research
|
February 16, 2015
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
John M Kane, Aleksandar Skuban, John Ouyang, et al.
The American Journal of Psychiatry
|
April 18, 2015
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Christoph U Correll, Aleksandar Skuban, John Ouyang, et al.
Page
of 6